Technology | June 02, 2010

FDA Clears Home Blood Coagulation Testing System

June 2, 2010 – A portable point-of-care prothrombin time/international normalized ratio (PT/INR) analyzer was released this week. The system detect blood clotting time for patients stabilized on oral anticoagulation medications such as warfarin. The CoaguSense PT/INR monitoring system was recently cleared by the U.S. Food and Drug Administration (FDA) for use by patients in the home by prescription.

The analyzer is also now clinical laboratory improvement amendments (CLIA) waived for use in physician offices. The product consists of a low-cost meter and disposable test strip. Medical professionals can order the system through Abbott Point of Care, which formed an exclusive agreement with CoaguSense to sell and market the CoaguSense PT/INR Monitoring System.

The device is designed for patients requiring the oral anticoagulant warfarin on a long-term basis. For many patients, their blood coagulation levels are checked too infrequently to reduce the risk of bleeding and thrombotic complications. The device offers the ability to test weekly at home.

The routine measurement of prothrombin time is a test performed to control the safe and effective management of oral anticoagulation therapy. Recently, Medicare expanded reimbursement to cover patient self-testing (PST) of prothrombin time at home for the majority of those indications.

The CoaguSense PT/INR Monitoring System is intended for use by properly selected and trained patients or their caregivers on the order of the treating physician. Users should be stabilized on oral anticoagulation medications such as warfarin prior to initiating self-testing with the system. Patients who have recently taken or are currently taking any type of heparin or low molecular weight heparin anticoagulant should not use the system and should consult their doctor. The device is not to be used for screening purposes.

For more information:

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init